Dr Michael Wang Discusses the Importance of Biosimilars in Cancer Care

February 18, 2020

Using biosimilars to reduce costs of cancer care is necessary, says Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at MD Anderson Cancer Center.

Using biosimilars to reduce costs of cancer care is necessary, says Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at MD Anderson Cancer Center.

Transcript:

What is your position on biosimilar use inpatients with diffues large B-cell lymphoma? Are you comfortable using biosimilar anticancer therapeutics?

The concept of biosimilars is very powerful and is totally a useful concept. Our healthcare costs are so high, if we don't use biosimilars, our prices will never go down. We cannot afford it. Also biosimilars, in large part, have very good efficacies. I encourage the idea and also the practice of using biosimilars. I am comfortable using biosimilars all the time. When my institution approves of a biosimilar, I have no problem with using it at all. In fact, I'll use it more than the regular high-priced drug.

Related Content:

Interviews